SEC Form S-8 filed by Janux Therapeutics Inc.
As filed with the Securities and Exchange Commission on February 27, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Janux Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
82-2289112 |
(State or other jurisdiction of incorporation or organization) |
|
(IRS employer identification number) |
|
|
|
10955 Vista Sorrento Parkway, Suite 200, San Diego, California |
|
92130 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
2021 Equity Incentive Plan
2021 Employee Stock Purchase Plan
(Full titles of the plans)
David Campbell, Ph.D.
President and Chief Executive Officer
Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway, Suite 200
San Diego, California 92130
(858) 751-4493
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
Kenneth J. Rollins, Esq.
Edmond J. Lay, Esq.
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
(858) 550-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☒ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☐ |
Emerging growth company |
|
☐ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
The Registrant is filing this Registration Statement on Form S-8 for the purpose of registering an additional 2,953,230 shares of common stock under the Janux Therapeutics, Inc. 2021 Equity Incentive Plan and an additional 590,646 shares of common stock under the Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan.
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.
The Registrant previously registered shares of common stock for issuance under its 2021 Equity Incentive Plan and its 2021 Employee Stock Purchase Plan under Registration Statements on Form S-8, filed with the Securities and Exchange Commission on June 11, 2021 (File No. 333-257039), March 18, 2022 (File No. 333-263712), March 10, 2023 (File No. 333-270470) and March 8, 2024 (File No. 333-277797).
Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.
Item 8. Exhibits.
The exhibits to this Registration Statement are listed below:
Exhibit |
|
Exhibit Description |
|
|
|
4.1 |
|
|
|
|
|
4.2 |
|
|
|
|
|
4.3 |
|
|
|
|
|
5.1 |
|
|
|
|
|
23.1 |
|
|
|
|
|
23.2 |
|
|
|
|
|
24.1 |
|
Power of Attorney (included on the signature page to this Registration Statement). |
|
|
|
99.1 |
|
|
|
|
|
99.2 |
|
|
|
|
|
107 |
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 27, 2025.
|
|
JANUX THERAPEUTICS, INC. |
|
|
|
|
|
Date: February 27, 2025 |
|
By: |
/s/ David Campbell, Ph.D. |
|
|
|
David Campbell, Ph.D. |
|
|
|
President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Campbell and Maria Dobek, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ David Campbell, Ph.D. |
|
President and Chief Executive Officer and Director |
|
February 27, 2025 |
David Campbell, Ph.D. |
|
(Principal Executive and Financial Officer) |
|
|
|
|
|
|
|
/s/ Maria Dobek |
|
Vice President, Accounting |
|
February 27, 2025 |
Maria Dobek |
|
(Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ Ron Barrett, Ph.D. |
|
Chairperson of the Board of Directors |
|
February 27, 2025 |
Ron Barrett, Ph.D. |
|
|
|
|
|
|
|
|
|
/s/ Vickie Capps |
|
Director |
|
February 27, 2025 |
Vickie Capps |
|
|
|
|
|
|
|
|
|
/s/ Eric Dobmeier |
|
Director |
|
February 27, 2025 |
Eric Dobmeier |
|
|
|
|
|
|
|
|
|
/s/ Sheila Gujrathi, M.D. |
|
Director |
|
February 27, 2025 |
Sheila Gujrathi, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Natasha Hernday |
|
Director |
|
February 27, 2025 |
Natasha Hernday |
|
|
|
|
|
|
|
|
|
/s/ Winston Kung |
|
Director |
|
February 27, 2025 |
Winston Kung |
|
|
|
|
|
|
|
|
|
/s/ Alana McNulty |
|
Director |
|
February 27, 2025 |
Alana McNulty |
|
|
|
|
|
|
|
|
|
/s/ Jake Simson, Ph.D. |
|
Director |
|
February 27, 2025 |
Jake Simson, Ph.D. |
|
|
|
|